The official twitter handle of Women In Gastroenterology Initiative
Pakistan
Joined March 2023
- Tweets7.3K
- Following379
- Followers868
- Likes11.3K
WomenInGastroenterology retweeted
#ESMO26 Presidential Session and concomitant publication in @Annals_Oncology
ARTEMIS-011 Ris-Rez vs gem/doce in prev treated osteosarcoma shows PFS benefit but modest ORR and OS immature
A landmark phase III result opening the door to ADCs in osteosarcoma
@OncoAlert
WomenInGastroenterology retweeted
DeLLphi-304: 🫁
Tarlatamab sustained its OS benefit at 23-month follow-up, improving median OS to 13.6 vs 8.4 months (HR 0.62)
@OncoAlert #ESMO26 @ESMO_Open #ESMOAmbassadors #LungCancer #ESMOcommunity @myESMO
📢 #ESMO26 concomitant paper: Extended follow-up of #tarlatamab in patients with small-cell lung cancer after platinum-based chemo in the phase 3 DeLLphi-304 study.
🔗shorturl.at/QFAwC
@JulienMazieres @pedrofrocha @UniklinikEssen @medizinischefakultaet @g_mountzios
WomenInGastroenterology retweeted
Just left IFEMA, incredibly excited abt all the amazing work #ESMO2026. Technological advances that I was sceptical would work in pts are now producing real clinical benefit! Grateful to be back at the presidential in Madrid w/ @tompowles1! @Uromigos @LAUrology_NL @NKI_nl
WomenInGastroenterology retweeted
#ESMOconversations At #ESMO26, it is always a place for reuniting @myESMO
Many smiles 😊 hands shake 🤝 & hugs 🫂for the great people I know, I learn, & I collaborated with previously and will continue to be with in coming life journeys! ❤️❤️
💬 #ESMOconversations: Share some of the impactful professional advice you have received.
📸 If you are attending #ESMO26, reconnect with the people who inspired you, take a photo together, and tell us why that connection has been meaningful to your professional journey, using #ESMOconversations.
WomenInGastroenterology retweeted
~10 yrs #DancingWithNED after #mTNBC dx, & no ongoing tx, I’m an outlier, a 🦄 in the MBC community.
NED/NEAD 🚫 cured. Stable disease w/o NED is still treatment success!
Why me? 🤔Science, biology & luck🤷🏼♀️ We need durable responses for ALL.
#bcsm #FundMBCResearch @metavivor
Day 27
No Evidence of Disease (NED) means scans show no detectable metastatic breast cancer, but it is not a cure. Hidden cancer cells may remain, which is why ongoing treatment and monitoring are often needed.
Don’t ignore stage IV.
#metavivor #METober
WomenInGastroenterology retweeted
Vedolizumab or ustekinumab for pediatric UC? In 108 patients under 21 (Stanford), 1-year steroid-free remission in UC/IBD-U was 61% on vedolizumab vs 32% on ustekinumab; in Crohn disease, 64% vs 67%. Trials still needed. #IBD #PedsIBD
doi.org/10.1002/jpn3.70198
WomenInGastroenterology retweeted
Upper GI #RapidOral session at @myESMO #ESMO26
iKRAS G12D PDAC HRS-4642 + chemo + PDL1
🤩Perioperative🤩
✅ORR - above 60%
🤔R0 - 100%
😊Reports pathological response
💪Good signal, let’s pursue
#ESMOAmbassadors
WomenInGastroenterology retweeted
SWITCH trial: ADC switching
25% HR+ 75% TNBC
ORR: 0-8.3%, PFS 1.4-3.0 mo
@OncoAlert #ESMO26
WomenInGastroenterology retweeted
#ESMO26 Today the thoracic oncology community celebrates:
🏆 The major advances in the fight against lung cancer reported at @myESMO
🎉The birthday of @JordiRemon 🥳 (great discussant!)
🐣 The new member of the lung cancer family on the way!!! ….and the best ever pregnant discussant of all times @DrJNaidoo
So happy to be part of this superfamily
May God bless you all and our patients
#ESMOAmbassadors
WomenInGastroenterology retweeted
Really enjoyed being part of the @OncoDaily Bladder Cancer Grand Rounds at #ESMO26
So much is changing in bladder cancer but there are still plenty of questions we don’t have answers to
Special thanks to @AndreaNecchi for bringing us together and leading such a great discussion
Bladder Cancer Grand Rounds happening in Madrid! 🇪🇸
Two sessions bringing the latest evidence and worldwide clinical experience together at OncoDaily Grand Rounds during ESMO 2026.
Part 1, chaired by Prof. @AndreaNecchi, featured educational lectures on:
• Radical cystectomy and bladder preservation — Dr. @DrFelixGuerrero
• Systemic therapy advances in localised bladder cancer — Prof. @AndreaNecchi
• Treatment selection and sequencing in advanced urothelial carcinoma — Dr. Sara Coca Membribes (@scocmem)
• Practical management, toxicity and monitoring — Dr. María José Juan Fita
Part 2, chaired by Dr. María José Juan Fita, brought worldwide experience to the discussion through shared clinical cases. The panel explored the use of enfortumab vedotin plus pembrolizumab, perioperative strategies, treatment sequencing and bladder preservation and how access and reimbursement shape everyday decisions.
Joining the discussion were Dr. Sara Coca Membribes (@scocmem) (United Kingdom), Dr. @DrFelixGuerrero (Spain), Dr. Helena Kremer (Brazil), Dr. Kelvin Yan (Hong Kong, China), Dr. @DrUddiGoswami (India), Dr. Samvel Bardakhchyan (Armenia), Dr. Lazar Popovic (@LazarPo31787807) (Serbia), Prof. Chunguang Yang (China), Dr. Javier Molina Cerrillo (@JaviMolinaC) (Spain) and Dr. Kleida Mati (Albania).
The same clinical scenario can lead to very different treatment choices across countries. Sharing these experiences helps us understand the gaps and what we can do better together.
Thank you to all our faculty and participants for such an open and engaging discussion!
This independent educational activity is supported by a grant from @AstellasUS.
#OncoDaily #ESMO2026
WomenInGastroenterology retweeted
🆙#ESMO26 Proffered Paper: #LCSM Non-Mets
🔥DeLLphi-304: Tarlatamab in Previously Treated SCLC: Extended Follow-Up of Overall Survival From the Phase 3 Trial
🎙️ @charlesrudin
🔢3808O
🎯Durable OS Benefit at 23-Mo Median Follow-Up
🎯mOS 13.6 vs 8.4mo (HR 0.62); 18-Mo OS 42% vs 24%
🎯Grade≥3 TRAEs 28% vs 63%
☑️NCT05740566
🔗 cslide.ctimeetingtech.com/es…
@OncoAlert @Larvol @myESMO @IASLC
🆙#ESMO26 Proffered Paper: #LCSM Non-Mets
🔥DeLLphi-304: Tarlatamab in Previously Treated SCLC: Extended Follow-Up of Overall Survival From the Phase 3 Trial
🎙️ @charlesrudin
🔢3808O
🎯Durable OS Benefit at 23-Mo Median Follow-Up
🎯mOS 13.6 vs 8.4mo (HR 0.62); 18-Mo OS 42% vs 24%
🎯Grade≥3 TRAEs 28% vs 63%
☑️NCT05740566
🔗 cslide.ctimeetingtech.com/es…
@OncoAlert @Larvol @myESMO @IASLC
WomenInGastroenterology retweeted
Primary results from BRIDGET ph2 trial presented by @drsarahsam and published in @ESMO_Open. Adding tucatinib to HP after an isolated intracranial PD led to impressively long PFS (59% free from PD or death at 18mo!!). Reasonable strategy from next Monday in TKI-naive patients.
WomenInGastroenterology retweeted
👏 Huge congratulations to my colleague @Maxime_Borgeaud for presenting his excellent poster on liquid biopsy in fusion-driven NSCLC at #ESMO26!
Great to see the results of his work at Gustave Roussy!
And on a personal note, I couldn’t be happier to welcome him back to Geneva @hug_ge after a fantastic year at Gustave Roussy!
Looking forward to having you back on the team, Maxime! 🚀
#ESMO26 #ESMOAmbassadors #LungCancer #NSCLC #LiquidBiopsy #ThoracicOncology
WomenInGastroenterology retweeted
Really important topic
It highlights the importance of adequately #designed #trials when assessing #optimisation of care approaches.
Most importantly, #patient on the #centre, securing no benefit lost or any form of detrimental effect
@myESMO #ESMO26
#ESMOAmbassadors
#ESMO26: Data from the MOIO trial were inconclusive regarding whether de-escalating #immunotherapy is beneficial after previous response to 6-month #ImmuneCheckpointInhibitor therapy in patients with a range of advanced #SolidTumours.
#InsightsbyESMO ➡️ow.ly/9WhK51002S2
WomenInGastroenterology retweeted
🆙#ESMO26 Proffered Paper: #LCSM Non-Mets
🔥ASTRIDE: Randomized Trial of Serplulimab or Atezolizumab Plus Chemotherapy in USA Patients With Extensive-Stage Small Cell Lung Cancer
🎙️ @drgandara
🔢3809O
🎯Serplulimab Numerically Longer OS vs Atezolizumab
🎯mOS 12.4 vs 10.2m, HR 0.82; 24-Mo OS 32.2% vs 17.6%
☑️NCT05468489
🔗 cslide.ctimeetingtech.com/es…
@OncoAlert @Larvol @myESMO @IASLC
🆙#ESMO26 Proffered Paper: #LCSM Non-Mets
🔥ASTRIDE: Randomized Trial of Serplulimab or Atezolizumab Plus Chemotherapy in USA Patients With Extensive-Stage Small Cell Lung Cancer
🎙️ @drgandara
🔢3809O
🎯Serplulimab Numerically Longer OS vs Atezolizumab
🎯mOS 12.4 vs 10.2m, HR 0.82; 24-Mo OS 32.2% vs 17.6%
☑️NCT05468489
🔗 cslide.ctimeetingtech.com/es…
@OncoAlert @Larvol @myESMO @IASLC
WomenInGastroenterology retweeted
#ESMO26 The brilliant Dr. @marinagarassino with biomarker analysis from the phase III KEYNOTE 671 study of perioperative pembrolizumab for resectable NSCLC showing association of T-cell inflamed gene expression profile and TMB with efficacy. Benefit across subgroups; inflamed profile associated with better prognosis. #ESMOAmbassadors
WomenInGastroenterology retweeted
A magical evening at the #ESMO26 Presidential Dinner in Madrid! ✨🇪🇸
Beyond the science, it’s the friendships, shared purpose and connections across borders that make this community so special.
Grateful to be part of it, and excited for the collaborations ahead! ❤️🌍
@myESMO
WomenInGastroenterology retweeted
🆙#ESMO26 Poster: #LCSM
🔥MARIPOSA: Dose Modifications to Manage Adverse Events (AEs) in 1L EGFR-Mutated Advanced NSCLC: Post Hoc, Exploratory Analyses From the Phase 3 Trial
🎙️ @ShirishGadgeel
🔢2650P
🎯Ami Dose Modification (Mostly Interruption, n=363) Improved Grade≥2 AEs in Most Pts
🎯Rash 80%, Paronychia 77%, Peripheral Edema 82%
🎯Median Time to Improvement <1 Month (~2 Weeks for Grade≥3)
☑️NCT04487080
🔗 cslide.ctimeetingtech.com/es…
@OncoAlert @Larvol @myESMO @IASLC @EGFRResisters
WomenInGastroenterology retweeted
#ESMO26 Dr. Shun Lu gives us the final analysis of the phase III Neotorch trial: perioperative toripalimab + chemotherapy for resectable stage II/III NSCLC. With 48.2m follow up, EFS 0.52 (median NR vs 20), MPR 47% vs 9%, pCR 26% vs 1%, OS HR 0.66. #ESMOAmbassadors
